Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
nVent completes USD 1.75 billion acquisition of Maverick Power

nVent completes USD 1.75 billion acquisition of Maverick Power

BitgetBitget2026/10/01 11:46
  • nVent completed its acquisition of Maverick Power for USD 1.75 billion, subject to customary purchase price adjustments.
  • Deal terms include potential additional cash consideration of up to USD 550 million tied to performance metrics in 2027 and 2028.
  • Maverick Power manufactures engineered power distribution and infrastructure equipment for data centers, expanding nVent’s data center power platform.
  • Maverick Power is headquartered in McKinney, Texas, with about 900 employees across Texas and Arizona.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nVent Electric plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010745PRIMZONEFULLFEED9837846) on October 01, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12